Avadel Pharmaceuticals plc

Contributing Author

Recent Articles by Avadel Pharmaceuticals plc

Feb-10	Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing GlobeNewswire
Jan-12	Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes GlobeNewswire
Dec-18	Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ Trial in Idiopathic Hypersomnia GlobeNewswire
Dec-05	Announcement relating to despatch of Rule 15 proposal GlobeNewswire
Dec-03	Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting GlobeNewswire
Dec-01	Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting GlobeNewswire
Nov-17	Avadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal" GlobeNewswire
Nov-14	Avadel Receives Unsolicited Proposal from Lundbeck GlobeNewswire
Nov-05	FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc GlobeNewswire
Nov-04	Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire
Oct-22	Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement GlobeNewswire
Oct-13	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-16	Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding GlobeNewswire
Sep-10	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-05	Avadel Pharmaceuticals to Present New Data on LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 GlobeNewswire
Sep-03	Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd GlobeNewswire
Aug-29	Avadel Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
Aug-07	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-07	Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance GlobeNewswire
Jul-31	Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7 GlobeNewswire
Jul-21	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-30	Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation GlobeNewswire
Jun-16	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-05	Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia GlobeNewswire
May-29	Avadel Pharmaceuticals to Present New Data on LUMRYZ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025 GlobeNewswire
May-29	Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-13	Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer GlobeNewswire
May-13	Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference GlobeNewswire
May-08	Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-07	Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance GlobeNewswire
May-06	Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction GlobeNewswire

Avadel Pharmaceuticals plc

Recent Articles by Avadel Pharmaceuticals plc

Upgrade your Finviz experience